Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited has issued a supplemental announcement concerning the disclosure of directors’ and employees’ emoluments in its 2021 and 2022 annual reports. The update provides detailed information on the fees, salaries, allowances, and retirement benefits of the company’s directors and chief executive officer, reflecting changes in the company’s executive structure and compensation over the two years.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company incorporated in Bermuda with limited liability, primarily operating in the pharmaceutical industry. The company focuses on the development and distribution of pharmaceutical products and related services.
Average Trading Volume: 7,809,922
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.04B
See more data about 0512 stock on TipRanks’ Stock Analysis page.